## Alternatives to Eye Drops for Glaucoma Treatment
Glaucoma is a chronic and progressive eye condition that can lead to vision loss if left untreated. Traditionally, the primary treatment for glaucoma has been the use of topical eye drops to lower intraocular pressure (IOP). However, poor adherence to eye drop regimens is a major challenge, with studies showing that over 50% of glaucoma patients do not adhere to their prescribed treatment plans [1]. This can be due to factors such as difficulty applying the drops, forgetfulness, and side effects like eye irritation.
To address these issues, researchers and clinicians have been exploring alternative drug delivery systems for glaucoma treatment. These alternatives aim to provide sustained, controlled release of glaucoma medications while reducing the burden on patients. Here are some of the promising alternative treatments that are currently in development or have recently been approved:
Intracameral Implants
The iStent infinite® from Glaukos represents a significant advancement in the treatment of open-angle glaucoma. This first-of-its-kind, standalone implantable device is designed to provide long-term intraocular pressure (IOP) control for patients whose glaucoma is inadequately managed by prior medical and surgical interventions.[1][3]
The iStent infinite features three wide-flange, anatomically-designed, heparin-coated titanium stents preloaded into an elegant, precision-engineered injector system. By restoring physiologic outflow and creating arcs of flow spanning up to 240° around Schlemm’s canal, the iStent infinite offers broader coverage than other MIGS procedures while minimizing tissue disruption.[1] This unique design allows surgeons to treat a variety of glaucoma patients, including those undergoing cataract surgery or as a standalone procedure.[3]
Pivotal trial data has demonstrated the iStent infinite’s exceptional safety and effectiveness, even in this challenging patient population. At 12 months, the device achieved clinically significant IOP reduction, with a majority of patients meeting the primary responder endpoint of ≥20% IOP lowering without medication increase or safety events.[4] Importantly, the iStent infinite does not preclude future interventions, making it a valuable addition to the glaucoma treatment algorithm.[1][5]
By providing a safe, micro-invasive surgical option to address rampant rates of medication non-compliance and disease progression, the iStent infinite empowers surgeons to intervene earlier and potentially delay or prevent more invasive procedures for their glaucoma patients.[1][3] This innovative technology represents an important step forward in the management of this chronic, sight-threatening condition.
Citations:
[1] https://theophthalmologist.com/subspecialties/to-infinity-and-beyond
[2] https://www.glaukos.com/glaucoma/istent-infinite-reimbursement/
[3] https://www.glaukos.com/glaucoma/products/istent-infinite/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722368/
[5] https://glaucomatoday.com/articles/2022-may-june-insert/new-surgical-technologies-to-expand-your-treatment-algorithm
One of the most exciting new developments is the FDA-approved intracameral implant Durysta (bimatoprost implant) [2]. This is a dissolvable implant that is injected into the anterior chamber of the eye and provides sustained delivery of the prostaglandin analogue bimatoprost designed to last 4 months but has been shown to last for up to 24 months [3].
The Durysta Implant eliminates the need for daily prostaglandin analogue eye drops, which can improve adherence and reduce side effects related to preservatives in eye drops. In clinical trials, over 40% of patients did not require any additional treatment for at least a year after receiving the Durysta implant [4]. This represents a significant improvement over the daily drop regimen.
Other intracameral implant technologies are also in development, such as the iDose sustained-release travoprost implant from Glaukos [5]. These implants are designed to be refillable or replaced periodically to provide long-term IOP control. This option is now available although it is very expensive. We can check if your insurance covers this option.
### Intravitreal Injections
Another approach is to deliver glaucoma medications via intravitreal (into the vitreous humor) injections. This includes the GB-401 injectable implant from Graybug Vision, which is designed to provide sustained delivery of a prostaglandin analogue for up to 1 year . This is not yet available in all countries and may not be FDA approved.
Intravitreal injections bypass the need for topical eye drops and can achieve higher drug concentrations in the target tissues. However, this route of administration does carry a higher risk of complications such as endophthalmitis, retinal detachment, and cataract formation compared to topical drops .
### Punctal Plugs
Punctal plugs are tiny devices that are inserted into the tear ducts to block drainage of tears from the eye. This allows the medication to be absorbed through the tear film for a prolonged period.
One example is the Evolute punctal plug from Mati Therapeutics, which is designed to continuously release a prostaglandin analogue into the tear film . This approach aims to provide IOP lowering effects while reducing the need for daily eye drops. Again, this may not be available in the USA due to FDA approval constraints.
Punctal plugs are a relatively non-invasive option, but their long-term efficacy and safety profile is still being evaluated in clinical trials.
### Topical Drug Delivery Systems
In addition to implantable and injectable devices, researchers are also exploring new topical drug delivery systems that can provide sustained release of glaucoma medications.
These include dissolvable ocular inserts made of hydrogels or polymers that can be placed in the conjunctival sac or fornix of the eye. Examples include the OTX-TIC travoprost insert from Ocular Therapeutix and the ENV515 travoprost insert from Envisia Therapeutics .
These topical systems aim to improve drug bioavailability and reduce the need for frequent dosing compared to traditional eye drops. However, they still require periodic administration by the patient, unlike the implantable or injectable options. Again, check with your doctor to see if or when this option will be available in the USA.
### Combination Therapies
Many glaucoma patients require multiple medications to achieve their target IOP. To address this, some of the new drug delivery systems are being developed to incorporate combination therapies.
For example, the iDose implant from Glaukos can be loaded with a combination of travoprost and latanoprost to provide dual-drug therapy [5]. This could potentially eliminate the need for patients to use multiple eye drop bottles. As these two medications are of the same class, it is unlikely a commercial product will be useful.
### Potential Benefits of Alternative Delivery Systems
The key advantages of these alternative glaucoma drug delivery systems include:
1. Improved adherence: By reducing or eliminating the need for daily eye drop administration, these systems can significantly improve patient adherence and persistence with treatment.
2. Reduced side effects: Many of these systems use lower total drug doses and avoid the use of preservatives like benzalkonium chloride, which can cause ocular surface irritation.
3. Convenience: Implantable and injectable options provide long-lasting IOP control with infrequent administration, reducing the treatment burden on patients.
4. Targeted drug delivery: Some systems are designed to deliver the medication directly to the target tissues in the eye, improving drug bioavailability.
### Challenges and Limitations
While these alternative delivery systems hold great promise, they also face some challenges:
1. Cost: The manufacturing and surgical implantation of these devices may be more expensive than traditional eye drops.
2. Safety profile: Longer-term safety data is still needed, especially for the more invasive implantable and injectable options.
3. Reversibility: Some of these systems, like the Durysta implant, are not reversible, which could be a concern for patients.
4. Combination therapy limitations: Most of the current systems only allow for single-drug delivery, whereas many glaucoma patients require multiple medications.
5. Accessibility: The availability and adoption of these new technologies may be limited, at least initially, to specialized glaucoma centers and practices.
### Conclusion
The development of alternative drug delivery systems for glaucoma represents an exciting advancement in the field. By addressing the key challenges of poor adherence and side effects associated with traditional eye drops, these new technologies have the potential to significantly improve outcomes for glaucoma patients.
As research and clinical experience with these systems continues to evolve, we can expect to see more options become available that provide sustained, targeted IOP control with enhanced convenience and tolerability for patients. While challenges remain, the future of glaucoma treatment is moving towards a “drop-less” paradigm that could transform the management of this chronic, sight-threatening disease.
[1] Devices and Treatments to Address Low Adherence in Glaucoma Patients: A Narrative Review. [1]
[2] Implant Offers an Alternative to Eye Drops for Glaucoma Patients. [4]
[3] Alternative Drug Delivery Systems For Glaucoma: A Dropless Future?. [3]
[4] Ibid. [3]
[5] iDose Sustained-Release Travoprost Implant for Glaucoma. Glaukos. https://www.glaukos.com/idose/
GB-401 Injectable Implant for Glaucoma. Graybug Vision. https://graybug.com/pipeline/gb-401/
Intravitreal Injections: Complications. American Academy of Ophthalmology. https://www.aao.org/eye-health/treatments/intravitreal-injections-complications
Evolute Punctal Plug. Mati Therapeutics. https://matitherapeutics.com/evolute/
OTX-TIC (Travoprost Intracanalicular Insert). Ocular Therapeutix. https://www.ocutx.com/pipeline/otx-tic/
ENV515 Travoprost Implant. Envisia Therapeutics. https://www.envisiatherapeutics.com/pipeline/env515/
Citations:
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821329/
[2] https://eyewiki.aao.org/Alternative_Treatments_for_Glaucoma
[3] https://glaucoma.org/articles/alternative-drug-delivery-systems-for-glaucoma-a-dropless-future
[4] https://clinicalconnection.hopkinsmedicine.org/news/implant-offers-an-alternative-to-eye-drops-for-glaucoma-patients
[5] https://glaucomatoday.com/articles/2016-nov-dec/preservative-free-alternatives